Journal of Natural Science Review

Vol. 2, No. 4, 2024
https://kujnsr.com
e-ISSN: 3006-7804

Understanding Adverse Drug Effects and the Clinical Pharmacist's Role in Their Management

Farid Ahmad Tanin

Kabul University, Faculty of Pharmacy, Department of Clinical Pharmacy, Kabul, Afghanistan
✉E-mail: faridtanin@yahoo.com (corresponding author)

ABSTRACT

Pharmacological interventions are the cornerstone of modern medical treatment, designed to address specific diseases, alleviate symptoms, and improve patients' quality of life. However, misconceptions persist regarding drug effects, such as the belief that all pharmacological effects are beneficial and that all side effects are adverse. Clinical Pharmacists (CPs) play a crucial role in managing drug-related problems, but their contributions remain underrecognized in Afghanistan. This study aims to address these misconceptions and emphasize the role of CPs in managing adverse drug effects (ADEs). A comprehensive literature review was conducted to explore the categorization of drug effects and the role of CPs in ADE management. The findings reveal that pharmacological effects are not always the intended effects, and side effects are not always adverse. CPs are vital in identifying risk factors such as polypharmacy and specific drug characteristics, establishing therapeutic goals, and mitigating ADEs. In conclusion, drug ineffectiveness and lack of efficacy should be categorized as ADEs, and side effects that contribute to therapeutic outcomes should not be deemed adverse. Integrating CPs more effectively into healthcare systems is essential to optimize medication management, ensure safer treatments, and enhance patient outcomes.

ARTICLE INFO

Article history:

Received: Oct 26, 2024
Revised: Dec 10, 2024
Accepted: Dec 24, 2024

Keywords:

Adverse Drug Effects; Organotoxicity; Idiosyncratic Effects; Allergic Effects; Pseudoallergic Effects; Clinical Pharmacists

To cite this article: Tanin, F. A. (2024). Understanding Adverse Drug Effects and The Clinical Pharmacist's Role in Their Management. *Journal of Natural Science Review*, *2*(4), 1–35.
https://doi.org/10.62810/jnsr.v2i4.106
Link to this article: https://kujnsr.com/JNSR/article/view/106



INTRODUCTION

Pharmacologic and nonpharmacologic interventions are critical in managing diseases, with pharmacologic treatments often forming the cornerstone of care. Drugs used as pharmacologic interventions are not silver bullets to play with since, besides producing beneficial effects, they may cause several unintended effects (Tewabe et al., 2021). In order to differentiate between drug effects, several terms are used, which are sometimes confusing and need to be highlighted.

A beneficial effect of a medication that aligns with treatment goals and contributes positively to patient outcomes can be classified as a desirable or wanted effect (Volkan, 2020). In contrast, an effect that is negative or harmful, potentially leading to adverse outcomes but not severe enough to warrant discontinuation of the drug, is referred to as an

undesirable or unwanted effect (Schatz & Weber, 2015). The term "expected effect" pertains to the anticipated outcome or response to a medication based on clinical studies, pharmacological understanding, or past experiences, often aligning with intended effects (Fillmore et al., 1994). Conversely, an outcome or response to a medication that is not anticipated based on previous knowledge or clinical studies is identified as an unexpected effect. Reviewing the Adverse Drug Effects (ADEs) categories of drug effects is crucial in identifying and understanding them and providing insight into managing ADEs in patients.

While pharmacological agents can produce significant therapeutic benefits, they also cause ADEs, unintended and harmful responses that can occur following drug administration (Bailey et al., 2016), presenting significant challenges to patient safety and treatment efficacy (Schatz & Weber, 2015). Understanding the various categories of ADEs is essential for healthcare providers. ADEs constitute a significant pharmacotherapy concern, impacting patient safety, treatment outcomes, and healthcare costs (Sahilu et al., 2020). The complexity of drug interactions and individual patient responses necessitates careful evaluation and management to optimize therapeutic outcomes and minimize harm (Gabay & Spencer, 2021). ADEs can lead to increased healthcare costs, prolonged hospital stays, and, in some cases, even mortality. Providing information concerning different categories of drug effects with ADEs is crucial for their understanding, effective management, and prevention. Therefore, the drug effects categories are introduced as follows, and later on, a comprehensive discussion is made to provide more insight into ADEs and the role of CPs in their management.

Expected or Pharmacological Effects or Pharmacologic Effects (PEs) represent the primary desired therapeutic outcomes a medication is designed to achieve upon administration (Casey, 1997). These effects are essential for managing patient conditions, driven by the drug's mechanism of action. However, it is crucial to recognize that while we aim for these desired outcomes, they can sometimes lead to adverse consequences (White et al., 2012). Deviations in expected PEs represent a significant category of ADEs (Rohilla & Yadav, 2013). Continuum of PEs and decreased PEs due to lack of efficacy of ineffectiveness may occur and can lead to ADEs.

Potentiation of PEs may lead to toxic effects and encompass a significant concern in pharmacotherapy. Toxic effects arise from excessive drug exposure or accumulation, leading to harm (Osterhoudt & Penning, 2018). Risk factors include overdose, drug interactions, renal or hepatic impairment, and genetic factors affecting drug metabolism (Routledge, 2003).

Drug ineffectiveness and lack of efficacy are often used interchangeably, but they can have slightly different connotations depending on the context. Here is a breakdown. Lack of efficacy occurs when a medication, despite being administered correctly in terms of dose, route, interval, and duration, fails to achieve the intended therapeutic outcome. However, the definition is controversial (Murru et al., 2011).

Ineffectiveness refers to a situation where a medication fails to produce the desired therapeutic effect in a patient. This can occur despite the drug being administered at the correct dosage and frequency (Sacco et al., 2020). While both terms deal with the failure of a drug to achieve its intended therapeutic outcome, drug ineffectiveness often focuses on patient-specific factors. In contrast, lack of efficacy typically pertains to the drug's overall performance in clinical settings.

Side Effects (SEs) represent secondary effects of a medication that occur in addition to the PEs (Due, 2023) in therapeutic doses (Pichler, 2006). SEs, unlike allergic reactions or idiosyncratic reactions, are predictable and usually dose-dependent, reflecting the drug's primary PEs (Bangwal et al., 2020).

Allergic effects are immune-mediated reactions to a drug that occurs when the body's immune system identifies a drug or its metabolite as a foreign substance (Eliseeva & Balabolkin, 2016). This occurs when the immune system identifies a drug as harmful (Warrington et al., 2018). Allergic reactions represent a significant category of ADEs and can lead to serious complications. These reactions are not dose-related and are typically unpredictable, often arising only after the patient has been sensitized to the drug (Hacker, 2009). The usual mechanism of such effects consists of forming a covalent bond between a drug or its metabolite, the body's endogenous substances, and producing an allergen (Fragkas, 2020). Clinical manifestations of allergic effects follow known allergic patterns and range from mild skin reactions to anaphylaxis (S. Y. Kim et al., 2018). Other types include skin eruptions, serum sickness reactions, hemolytic anemia, thrombocytopenia, allergic gastroenteritis, systemic lupus erythematous, and so on (Sherman, 1971).

Pseudoallergic effects refer to reactions that mimic the symptoms of drug allergies. However, the underlying mechanism does not involve a reaction between a drug-derived antigen and antibodies or sensitized cells (Hein et al., 1999). Pseudoallergic reactions, also called non-allergic or non-immune-mediated reactions, constitute another category of unpredictable ADEs. While these reactions are often clinically similar to genuine immunologically mediated allergic reactions, they do not have immunological specificity (Pichler, 2019). Tables 1 and 2 summarize the drugs causing pseudoallergic effects and the symptoms following their occurrence.

Table 1: *Symptoms of pseudo-allergic reactions (Wang, 2011).*

System	Potential symptoms and signs
Respiratory	Sneezing, coughing, asthma attack, bronchospasm, choking, rhinitis, tachypnea, stridor
Gastrointestinal	Vomiting, nausea, abdominal pain, diarrhea
Cardiovascular	Angioedema, hypertension, angina pectoris, ventricular tachycardia, arrhythmias, cardiac arrest
Neuromuscular	Chills, confusion, muscle pain
Skin and mucosa	Rash, cyanosis, dermatitis, erythema, pruritus, skin eruptions, urticaria, conjunctivitis
Severe adverse reactions	Anaphylactic shock,

Table 2: *Drugs causing pseudoallergy (Zhang et al., 2017).*

Opioid	**Liposomal**	**Micelle-solubilized**	***NSAID**	****TCMIs**	**Other**
Morphine	Abelcet	Cyclosporine	Aspirin	Shuanghuanglian injection	Vitamin K1 injection
Codeine	Ambisome	Elite	Dolobid	Potassium dehydroandrogropolide succinate injection	Rocuronium
Meperidine	Amphocyl	Etoposide	Toradol	Shenmai injection	
Hydrocodone	Daunoxome	Fasturec	Lodine	Qingkailing injection	
Hydromorphon	Doxil	Taxol	Voltaren	Xuesaitong injection	
Oxycodone	Caelyx	Taxotere	Motrin	Danshen injection	
Methadone	Myocet	Vumon	Naprosyn	Andrographis injection	
Fentanyl	Visudyne		Ansaid		
Buprenorphine					

* Non - steroidal Antiinflammatory Drugs, ** Traditional Chinese medicine injections

Organotoxicity pertains to the degree to which a substance can harm living organisms (Duffus et al., 2007), which can occur at therapeutic doses, particularly in sensitive populations or with prolonged exposure. Drugs can produce some degree of organ toxicity with mechanisms unrelated to the actual mechanism of action (J. Kim & Shin, 2014).

Various types of organ toxicity can target specific organs or systems within the body (Pinky et al., 2021), mainly the heart muscle (Mudd et al., 2021), the liver (Pandit et al., 2012), the kidneys (Pazhayattil & Shirali, 2014) and some other organs.

Nephrotoxicity can be defined as the adverse effect of substances on renal function, potentially leading to acute kidney injury or chronic kidney disease (Barnett & Cummings, 2018). Hepatotoxicity denotes liver damage caused by drugs or other substances (P Sharma, 2014). Symptoms may include jaundice, elevated liver enzymes, and liver failure. Cardiotoxicity entails damage to the heart muscle, impairing its function and potentially leading to conditions like arrhythmias, heart failure, or myocardial infarction (Mladěnka et al., 2018).

Neurotoxicity involves damage to the nervous system due to exposure to toxic substances, including medications (Spencer & Lein, 2023). Symptoms may include confusion, seizures, neuropathy, and cognitive deficits.

Gastrointestinal (GI) toxicity encompasses a range of ADEs affecting the gastrointestinal tract, including nausea, vomiting, diarrhea, and ulceration (Pusztaszeri et al., 2007). These effects mainly occur with drugs administered orally since this route is often the preferred method for drug administration due to its affordability and convenience. However, specific individuals, particularly the elderly and pediatric populations, may have difficulty swallowing traditional tablets and hard gelatin capsules, potentially increasing the risk of adverse drug effects due to incorrect administration or non-compliance (Raihan et al., 2024).

Idiosyncratic effects or reactions encompass another category of drug effects characterized by their unpredictability. Unlike dose-dependent side effects, which occur

more frequently with higher doses, idiosyncratic effects can occur at any dose and often in individuals with no apparent risk factors (Glauser, 2000). These effects often result from genetic variations that affect drug metabolism or immune responses (Roth et al., 2003).

A clinical pharmacist is a healthcare professional specialized in optimizing medication use to ensure safe, effective, and individualized patient care, often working collaboratively with physicians and other healthcare providers. She/he plays a critical role in identifying and managing ADEs. He/she conducts thorough medication histories to understand a patient's complete drug profile, essential for recognizing potential allergic responses. By analyzing past medication use, CPs can provide informed recommendations on alternative therapies that may be safer for the patient (Alqurbi & Atiah, 2020). This proactive approach prevents allergic reactions and ensures patients receive the most appropriate treatment.

This complexity underscores the need for clear and accurate terminology to differentiate between beneficial and harmful drug effects, particularly in clinical settings. However, the terminology surrounding these effects can be confusing, leading to clinical practice and patient communication challenges.

In Afghanistan, pharmacological effects (PEs) are mostly considered beneficial, while side effects (SEs) are categorized as unbeneficial or adverse. However, whether this distinction accurately reflects the broader understanding of drug effects in clinical practice remains unclear. However, the terms used to describe drug effects, such as desirable, undesirable, expected, and unexpected, can be unclear and misinterpreted, potentially impacting patient care. For instance, an adverse effect not severe enough to require discontinuation may still be classified as undesirable. However, this term can be easily confused with more serious adverse effects. This confusion could lead to improper treatment decisions and miscommunication between healthcare professionals and patients, especially in regions like Afghanistan, where clinical terminology might differ from global standards. This article aims to address two key research questions:

1. Does the current understanding of pharmacologic effects (PEs) versus side effects (SEs) align with established clinical definitions?
2. How do misinterpretations and inconsistencies in the classification of drug effects influence clinical decision-making and patient outcomes, and how can these issues be addressed to improve patient care?
3. Can CPs, as specialized, well-educated healthcare team members, manage ADEs?

The current review explores the common misunderstandings and confusion regarding the classification of drug effects and their direct implications on clinical decision-making and patient care, especially here in Afghanistan. Explaining these terms through this study will improve their understanding of healthcare providers, enhancing patient education and leading to more informed treatment decisions. Furthermore, the results may contribute to optimizing patient outcomes, especially when language and terminology are not aligned with global clinical standards. Finally, the results of this study would improve future training

programs for healthcare providers, focusing on using standardized terminology to reduce misclassification and the resulting misunderstanding of drug effects.

METHODS AND MATERIALS

In order to address the mentioned issue, a comprehensive literature review was conducted to evaluate the accuracy of these perceptions and highlight the crucial role of CPs in managing and mitigating ADEs. Databases such as PubMed, ScienceDirect, and Google Scholar were searched using keywords related to drug effects and clinical pharmacy practice to select articles and collect proper data. The article's selection process was based on their relevance, methodological rigor, and contribution to the role of CPs in managing various types of ADEs. The most relevant studies published within the last 20 years and some relevant articles published in the past were also included. Data were synthesized to provide a comprehensive overview of several categories of drug effects, their relations with ADEs, and the role of CPs in their detection and management (Snyder, 2019).

RESULTS AND DISCUSSION

Adverse Drug Effects, defined as unintended and harmful outcomes resulting from medication use, range from mild to severe experiences that may necessitate further medical intervention(s) (Edwards & Aronson, 2000). Although ADEs are used in pharmacology to show the unintended effects of a medication, they are known as adverse drug experiences from the patient's point of view. In healthcare systems, they are categorized as adverse drug events, collectively abbreviated as ADEs. In order to find out when drug effects can be considered adverse and when they should not, we examine the different categories of drug effects mentioned above and discuss when they should be classified as ADEs. Some ADEs are predictable based on their known pharmacological effects, allowing them to be detected earlier and managed or avoided through proper planning and monitoring (Edwards & Aronson, 2000); however, many others are unpredictable and stem from unique individual factors, such as genetic variations or rare drug reactions (Daly, 2013) so require vigilance, prompt identification, and personalized interventions to minimize associated risks. CPs are important in addressing such events through proper interdisciplinary collaborative medication management and patient education (Giannitrapani et al., 2018).

Deviations in Expected PEs

Extensions of the drug's common pharmacodynamic effects directly stem from its mechanism of action (Rawlins, 1981). In some cases, the drug's pharmacological action leads to secondary effects that were not anticipated. Contributing risk factors for such effects include elevated dosages, extended usage, and individual vulnerabilities such as genetic predispositions, coexisting conditions, or interactions with other medications. For instance, the prolonged use of NSAIDs increases the risk of renal impairment (Möller et al., 2015). Similarly, corticosteroids can significantly increase the risk of hyperglycemia in susceptible individuals (Udoetuk et al., 2013). Drugs with a narrow therapeutic index are often associated with toxic effects. Lithium, a typical example, is widely used to treat bipolar disorder and

effectively stabilizes mood; however, even small increases in serum lithium levels can lead to toxicity (Oruch et al., 2014), which stems from its disruption of neurotransmitter signaling and ion transport, specifically affecting sodium and potassium channels, which can result in symptoms such as tremors and renal impairment. Consequently, regular monitoring is essential to prevent these adverse effects (Shahzad et al., 2017).

Drug interactions can markedly influence the way medications function in the body. For example, the interaction between warfarin and certain antibiotics can inhibit warfarin metabolism, thereby increasing the risk of bleeding (Vega et al., 2023). This highlights how a drug's intended effect, such as anticoagulation in the case of warfarin, can escalate into a potentially harmful outcome due to interactions or overdosage. Table 3 provides an overview of ADEs originating from pharmacologic effects.

Table 3: *Overview of ADEs caused by deviation of pharmacologic effects.*

Category	Description	Examples and Details
Extension of Usual Pharmacodynamic Properties	Effects directly related to the drug's mechanism of action, with potentiation of predictable effects (PEs).	High doses or prolonged use may cause renal impairment with NSAIDs or hyperglycemia with corticosteroids in susceptible individuals.
Toxic Effects	Occur with drugs having a narrow therapeutic index. Symptoms arise from pharmacological action exceeding safe thresholds.	Lithium toxicity due to slight serum level elevations affects neurotransmitter signaling and ion transport, leading to tremors and renal impairment.
Drug Interactions	Alteration in drug action due to interactions with other medications, resulting in enhanced or diminished effects.	Interaction between warfarin and antibiotics (e.g., inhibition of warfarin metabolism) increases the risk of bleeding.
Lack of Efficacy	Drug ineffectiveness that undermines treatment, potentially leading to ADEs, worsened conditions, or additional treatments.	Antidepressants: Ineffective engagement of neurochemical pathways (e.g., serotonin/norepinephrine) may worsen symptoms, requiring alternative treatments or new drugs.
Impact on Chronic Conditions	Lack of therapeutic effect in chronic conditions leads to disease progression, increased morbidity, and complications.	In tuberculosis, ineffectiveness can result in disease progression, complications, or diminished quality of life, necessitating individualized care.

Unintended effects arising from ineffectiveness or lack of efficacy represent another concern related to drug PEs and can be classified as ADEs. This issue can compromise the effectiveness of treatment, leading to suboptimal patient outcomes (Eichler et al., 2011). Identifying and addressing the factors contributing to lack of efficacy is essential for optimizing therapeutic outcomes and ensuring the best possible patient care (Enemchukwu et al., 2022). In order to assess treatment outcomes effectively and make necessary adjustments to patient care, healthcare professionals should understand these distinctions. The concern about ineffectiveness is especially crucial in managing chronic conditions. At the

same time, a lack of efficacy can arise when the drug fails to interact with its target properly or when the target is altered to impede drug binding or action. In the case of antidepressants, for example, if key neurochemical pathways, such as serotonin or norepinephrine signaling, are not adequately engaged, patients may experience persistent or worsening symptoms, requiring alternative treatment options. In these cases, patients may experience exacerbated depression and anxiety while on an ineffective antidepressant, potentially necessitating additional medications, each carrying its risks (Saltiel & Silvershein, 2015).

Although there is no specific data available to classify lack of efficacy and ineffectiveness as ADEs formally, they can be considered as such when they result in adverse health outcomes, increased morbidity, or the need for additional treatments. This occurs when a patient's condition worsens due to the lack of therapeutic effect from a prescribed medication, causing disease progression that may adversely affect treatment outcomes. As a result, complications or a reduced quality of life may arise, necessitating further interventions. These situations underscore the importance of continuous monitoring and personalized patient care in pharmacotherapy, particularly in conditions such as tuberculosis, where appropriate treatment is critical to prevent further complications (Alsultan & Peloquin, 2014).

Side Effects

As mentioned earlier, side effects (SEs) are often considered as adverse drug events (ADEs), although this is not always the case. Below, we discuss the unintended SEs that lead to ADEs, followed by a discussion on the beneficial SEs. Table 4 summarizes the key characteristics of SEs and provides related examples.

These effects can be either beneficial or harmful, and they are generally not the primary intended outcome of the drug. While often viewed as undesirable, some side effects (SEs) can be strategically utilized for therapeutic benefits (Edwards & Aronson, 2000).

SEs can sometimes complicate drug therapy. When amplified by drug interactions or overdose, they can lead to serious consequences. For example, the simultaneous use of an opioid pain reliever and a muscle relaxant can enhance central nervous system depression, resulting in increased drowsiness and confusion (Musich et al., 2020). Both drugs may act on similar neural pathways, resulting in cumulative effects.

Additionally, SEs can sometimes mask a drug's ineffectiveness. For example, nausea caused by a medication may overshadow its intended benefits, leading patients to discontinue its use, even though the drug has the potential to effectively address their condition (Blenkinsopp et al., 2008). This scenario may occur when ADEs overshadow therapeutic effects, leading to frustration and non-adherence. For instance, alpha receptor blockers, such as phenothiazine tranquilizers, are commonly prescribed to manage various conditions, including hypertension and psychiatric disorders. However, their use may also be associated with side effects such as sedation and orthostatic hypotension, which can complicate patient adherence or treatment effectiveness (Domino, 1962). This action can

sometimes result in side effects such as dizziness, lightheadedness, or orthostatic hypotension, especially when transitioning from lying to standing (Nash, 1990). The common side effect is hypotension, which may manifest as dizziness, fainting, or fatigue (Mudiyanse et al., 2024).

Another typical example is gastrointestinal disturbances associated with antimicrobial therapy. While effective in treating infections, antimicrobial agents can disrupt the normal gastrointestinal flora, leading to overgrowth of nonsusceptible bacteria, such as Clostridium difficile, which can result in symptoms ranging from mild diarrhea to more severe conditions like pseudomembranous colitis (Cerniglia & Kotarski, 2005). Bacterial overgrowth can lead to digestive tract disturbances such as diarrhea or colitis. The suppression of normal flora, which typically helps maintain a balanced gut microbiome, creates an environment where pathogenic bacteria can proliferate, resulting in ADEs. This imbalance can cause symptoms from mild digestive upset to severe infections, such as Clostridium difficile colitis (Zhang et al., 2015).

Similarly, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), through the inhibition of prostaglandin synthesis, can also cause disturbances. NSAIDs are widely used for their anti-inflammatory, analgesic, and antipyretic effects. However, they can lead to gastrointestinal complications, such as ulcers or bleeding, due to the reduction of protective prostaglandins in the stomach lining. Prolonged use of NSAIDs can also negatively impact renal function and contribute to fluid retention, leading to an increased risk of hypertension and kidney damage (Fokunang, 2018). They exert their action by inhibiting cyclooxygenase (COX) enzymes, essential for synthesizing prostaglandins, key mediators of inflammation. By reducing prostaglandin production, NSAIDs effectively alleviate pain and inflammation; however, this inhibition also reduces the protective effects of prostaglandins on the gastrointestinal mucosa, increasing the risk of gastric ulcers and bleeding.

Additionally, reduced prostaglandin production can affect renal function, leading to complications like fluid retention, kidney damage, and hypertension, particularly with long-term use (Gunaydin & Bilge, 2018). While this inhibition reduces inflammation and pain, it also leads to side effects (SEs) due to the decreased synthesis of protective prostaglandins, such as prostaglandin E2 and I2 in the gastrointestinal mucosa and thromboxane A2 in platelets. This reduction can result in gastrointestinal irritation, leading to symptoms like ulcers, bleeding, or perforation. Additionally, it may increase the bleeding risk due to impaired platelet aggregation, especially with long-term or high-dose use of NSAIDs (Patrignani et al., 2011).

Harnessing side effects (SEs) for pharmacological benefits can significantly improve treatment outcomes by utilizing unintended effects in a therapeutic context. For example, the sedative side effects of certain antihistamines can be beneficial for patients with insomnia, or the muscle-relaxing effects of certain medications can aid in the treatment of spasticity disorders. By understanding and appropriately managing these SEs, healthcare providers can optimize medication regimens for better patient outcomes (Casey, 1997). The

following examples highlight the significance of understanding and utilizing side effects (SEs) to improve patient care and treatment outcomes. Antihistamines, commonly used for treating allergies, have sedative SEs that can be advantageous in managing conditions like insomnia or anxiety. For example, diphenhydramine, an over-the-counter antihistamine, is frequently employed as a sleep aid due to its ability to promote drowsiness, helping individuals struggling with sleep disturbances. Recognizing and strategically applying such SEs allows healthcare providers to broaden the therapeutic use of medications, offering patients more effective, multifaceted treatment options (Natalia et al., 2019). While primarily prescribed for hypertension and heart conditions, beta-blockers can also help alleviate physical symptoms of anxiety, such as palpitations and tremors. This side effect is particularly beneficial for patients dealing with performance anxiety or stage fright, as it reduces the physical manifestations of nervousness, enabling individuals to manage anxiety in high-stress situations more effectively. Recognizing the potential for such beneficial side effects allows healthcare providers to use beta-blockers in broader clinical contexts, improving patient outcomes beyond their primary indications (Dooley, 2015).

Certain antidepressants, such as amitriptyline, are primarily used to treat depression but also serve as effective treatments for chronic pain conditions, including neuropathic pain and fibromyalgia. The drug's ability to modulate pain pathways, in addition to improving mood, highlights the multifaceted role of antidepressants in managing both mental health and physical conditions. This demonstrates how medications' side effects or secondary benefits can be harnessed to optimize therapeutic outcomes for patients with co-occurring conditions (Bonilla-Jaime et al., 2021).

While corticosteroids primarily reduce inflammation, they may also produce beneficial side effects, such as appetite stimulation in underweight patients (Fricke & Voderholzer, 2023) or those experiencing cachexia (Mattox, 2017). These effects can be valuable in improving nutritional intake and supporting overall recovery, particularly in patients with chronic illness or cancer, which continues to be one of the most widespread diseases worldwide, causing millions of deaths each year (Azad et al., 2024).

Selective serotonin reuptake inhibitors (SSRIs), commonly used as antidepressants, are also effective in treating premenstrual dysphoric disorder (PMDD) due to their mood-stabilizing effects. By increasing serotonin levels, SSRIs can alleviate the emotional symptoms associated with PMDD, such as irritability, depression, and anxiety, enhancing the patient's overall quality of life during the premenstrual phase (Tiranini, 2022).

Initially developed for epilepsy, gabapentin is now widely used for its side effects in managing neuropathic pain despite its primary indication being seizure control. The drug's ability to modulate nerve excitability and alleviate chronic pain has expanded its use in conditions like diabetic neuropathy and postherpetic neuralgia, demonstrating how certain side effects can offer significant therapeutic benefits beyond the drug's original intended use (Rose & Kam, 2002).

Table 4: *Overview of drug side effects.*

Category	Description	Examples
Complications in Drug Therapy	SEs can obscure drug effectiveness or result in adverse outcomes when amplified by drug interactions or overdoses.	- CNS depression from combining opioids and muscle relaxants. - Nausea masking a drug's benefits, causing discontinuation.
Specific Harmful SEs	- Hypotension from alpha receptor blockers (e.g., phenothiazines). - Gastrointestinal disturbances from antimicrobial therapy disrupting gut flora. - Gastrointestinal irritation and bleeding from NSAID use.	- Alpha-blockers cause dizziness and fainting due to low BP. - Antimicrobials lead to diarrhea or colitis by altering gut microbiota. - NSAIDs inhibit COX enzymes, reducing protective prostaglandins.
Beneficial SEs	SEs that enhance therapeutic outcomes can be intentionally utilized to improve patient care.	- Antihistamines like diphenhydramine aid sleep. - Beta-blockers reduce physical anxiety symptoms. - Antidepressants like amitriptyline treat neuropathic pain. - Gabapentin relieves neuropathic pain.
SEs Leveraged in Specific Conditions	Certain SEs are harnessed for unique therapeutic benefits beyond the drug's primary indication.	- Corticosteroids stimulate appetite in underweight patients. - SSRIs stabilize mood in PMDD. - Gabapentin repurposed for chronic pain.

Organotoxicity

Various types of organotoxicity can specifically target distinct organs or systems within the body (Table 5). This organ-specific toxicity can result from the direct harmful effects of drugs or chemicals, leading to dysfunction and, in some cases, irreversible damage. Each organ may respond differently to various toxic substances, which is important for clinicians to consider when assessing potential risks associated with drug therapy (Wu et al., 2016). Certain heavy metals, such as lead, have neurotoxic effects. Lead exposure can impair cognitive function, cause behavioral changes, and damage the nervous system, particularly in developing children. Chronic exposure to lead can result in permanent neurological damage, including memory loss, learning difficulties, and, in severe cases, encephalopathy. Understanding the neurotoxic potential of such metals is crucial for preventing and managing associated health risks (Bilge, 2016). Pharmacological agents like certain chemotherapeutic agents, such as Cisplatin, Vincristine, and Paclitaxel, as well as antiepileptics like Phenytoin (with long-term use), Valproic Acid, and Carbamazepine, are known for their neurotoxic potential. These

medications can cause peripheral neuropathy, characterized by symptoms like numbness, tingling, and pain, especially in the hands and feet. In some cases, prolonged use or high doses can lead to more severe neurological effects, including motor dysfunction and cognitive impairments. Monitoring for signs of neurotoxicity is essential to minimize the long-term impact on patients' nervous systems (Staff et al., 2019).

Common culprits of nephrotoxicity include NSAIDs, certain antibiotics (such as aminoglycosides), and contrast agents used in imaging studies. These drugs can impair kidney function, leading to acute kidney injury or chronic kidney damage with prolonged exposure. NSAIDs, for instance, can reduce renal blood flow, especially in patients with preexisting kidney conditions. Aminoglycosides can cause direct damage to renal tubular cells, and contrast agents may induce contrast-induced nephropathy, particularly in patients with compromised renal function. (Faucon et al., 2019). Careful dosing, monitoring, and patient selection are critical to prevent or mitigate nephrotoxic effects (Ferguson & Waikar, 2012).

Acetaminophen overdose, antiepileptics including phenytoin, lamotrigine, and felbamate, and certain antibiotics such as amoxicillin-clavulanate, erythromycin, and tetracyclines are known for their hepatotoxic potential.

Acetaminophen overdose, antiepileptics such as phenytoin, lamotrigine, and felbamate (Singh et al., 2016), and certain antibiotics like amoxicillin-clavulanate, erythromycin, and tetracyclines are recognized for their hepatotoxic potential (Pandit et al., 2012). These drugs can lead to liver damage, ranging from mild enzyme elevations to severe liver failure in extreme cases. Acetaminophen overdose, for example, can overwhelm the liver's ability to detoxify, leading to hepatocellular necrosis. Similarly, many antiepileptics and antibiotics can cause dose-dependent liver injury, highlighting the need for cautious use, especially in patients with preexisting liver conditions. Regular monitoring and performing liver function tests are essential for patients on drugs with known hepatotoxic risks. Dose adjustments or discontinuation may be necessary based on liver function test results and clinical symptoms (Jadhav et al., 2024).

Certain drugs can cause damage to the heart muscle or disrupt cardiac function. Notable examples include agents like doxorubicin (Iqubal et al., 2018) and anthracyclines, commonly used in chemotherapy and well-known for their cardiotoxic effects (Mudd et al., 2021). These drugs can induce heart failure by damaging the heart muscle through mechanisms such as oxidative stress, inflammation, and mitochondrial dysfunction. The cardiotoxicity of anthracyclines can lead to dose-dependent effects, with higher cumulative doses increasing the risk of long-term cardiac complications. Therefore, monitoring cardiac function during treatment with these agents is crucial to detect early signs of cardiotoxicity and mitigate adverse outcomes.

Common examples of drugs producing gastrointestinal toxicity are NSAIDs and chemotherapeutic agents. They, especially with chronic use, potentially result in conditions

like gastritis or peptic ulcers. Certain antimicrobials such as Clindamycin, Tetracyclines, Metronidazole, Fluoroquinolones, and Penicillins may also cause gastrointestinal issues.

Gastrointestinal toxicity is also a common occurrence with certain drugs. These toxicities can range from mild symptoms, such as nausea and diarrhea, to more severe conditions, like ulcers, bleeding, and gut perforation. Common examples of drugs that produce gastrointestinal toxicity include NSAIDs and chemotherapeutic agents. Chronic use of these medications can lead to conditions such as gastritis or peptic ulcers (Gelberg & States, 2020). Certain antimicrobials, including Clindamycin, Tetracyclines, Metronidazole, Fluoroquinolones, and Penicillins, are also associated with gastrointestinal issues (Heta & Robo, 2018). These drugs can disrupt the normal gastrointestinal mucosal barrier, alter the gut microbiota, or lead to direct irritation, resulting in symptoms like nausea, vomiting, diarrhea, or abdominal discomfort. Monitoring for gastrointestinal side effects is important, especially in patients on long-term treatment with these medications.

Dermatotoxicity refers to adverse skin reactions caused by certain medications, including rashes, photosensitivity, or more severe conditions like Stevens-Johnson syndrome. These reactions can vary in severity, ranging from mild skin irritation to life-threatening conditions that require immediate medical intervention. Certain drugs commonly associated with dermatotoxicity include Penicillins, Carbamazepine, Lamotrigine, NSAIDs, and Allopurinol (Fritsch & Sidoroff, 2000). Monitoring skin reactions is essential, and healthcare professionals should educate patients on recognizing early signs of dermatotoxicity, particularly when starting new medications or undergoing treatment regimens known to cause these effects.

Pulmonary toxicity is a profound adverse effect that causes inflammation and scarring of lung tissue, leading to impaired respiratory function. This condition can result from certain drugs, such as bleomycin, or inhaled substances. The damage to the lung tissue can lead to symptoms such as shortness of breath, cough, and chest pain. Early detection, proper assessment, and management are critical in preventing long-term lung damage (Reinert et al., 2013).

Ototoxicity, which refers to damage to the ear, can result in hearing loss or balance issues. It is commonly associated with aminoglycoside antibiotics, such as gentamicin, and certain chemotherapy drugs like Cisplatin (Schacht et al., 2012). These medications can cause damage to the inner ear structures, leading to symptoms such as hearing impairment, tinnitus, and vertigo. Monitoring for early signs of ototoxicity is crucial during treatment, especially for patients receiving high doses or prolonged therapy with these drugs, to prevent irreversible damage to auditory and vestibular functions.

Table 5: *Overview of organotoxic effects of drugs considered as ADEs.*

Type of Organotoxicity	**Description**	**Examples**
Neurotoxicity	Damage to the nervous system caused by drugs or heavy metals.	- Heavy metals: Lead - Chemotherapeutic agents: Cisplatin, Vincristine, Paclitaxel

		- Antiepileptics: Phenytoin (long-term use), Valproic Acid, Carbamazepine
Nephrotoxicity	Damage to renal function caused by specific drugs or substances.	- Common culprits: NSAIDs, aminoglycosides, contrast agents
Hepatotoxicity	Liver damage due to drug exposure.	- Overdose: Acetaminophen - Antiepileptics: Phenytoin, Lamotrigine, Felbamate - Antibiotics: Amoxicillin-Clavulanate, Erythromycin, Tetracyclines
Cardiotoxicity	Damage to the heart muscle or disruption of cardiac function.	- Common drugs: Doxorubicin, anthracyclines
Gastrointestinal Toxicity	Damage to the gastrointestinal tract leads to conditions like gastritis or peptic ulcers.	- Common drugs: NSAIDs, chemotherapeutic agents - Antimicrobials: Clindamycin, Tetracyclines, Metronidazole, Fluoroquinolones, Penicillins
Dermatotoxicity	Skin-related toxicities, including rashes, photosensitivity, or severe skin reactions.	- Common drugs: Penicillins, Carbamazepine, Lamotrigine, NSAIDs, Allopurinol
Pulmonary Toxicity	Lung damage caused by drugs or inhaled substances, leading to pneumonitis or pulmonary fibrosis.	- Common drugs: Bleomycin
Ototoxicity	Damage to the ear, causing hearing loss or balance issues.	- Common drugs: Aminoglycosides, Cisplatin

Allergic Effects

Allergic effects (Table 6) refer to a hypersensitive immune response triggered by a medication, leading to symptoms that can vary in severity, ranging from mild manifestations such as rashes to more severe reactions like anaphylaxis. A well-known example is penicillin allergy, where individuals may experience symptoms from mild skin reactions, such as rashes or hives, to life-threatening reactions, such as anaphylaxis, characterized by swelling, difficulty breathing, and a drop in blood pressure (Mirakian et al., 2015). Prompt detection of such allergies is crucial for informing future prescribing practices and mitigating adverse experiences (Steinman et al., 2011). Cross-sensitivity, also known as cross-reactivity, happens when a patient allergic or sensitive to one drug experiences a reaction to another because they share similar structural features or mechanisms of action (Sherman, 1971). This phenomenon is especially significant in antibiotics, where structural similarities can cause allergic reactions across various drug classes. Penicillins and cephalosporins, both β-lactam antibiotics, share a common β-lactam ring structure, increasing cross-sensitivity likelihood (Chaudhry et al., 2019). The structural similarity between penicillins and cephalosporins can lead to cross-sensitivity in patients allergic to penicillins. Similarly, sulfonamides, which belong to a different class of antibiotics, can also trigger allergic reactions in some individuals (Giles et al., 2019). Patients allergic to sulfonamides may also experience reactions to other medications containing similar sulfonamide groups, such as certain diuretics and

sulfonylureas used to manage diabetes (Johnson et al., 2005). Allergic reactions are important to ADEs (Luri et al., 2022).

Pseudoallergic Effects

Pseudoallergic effects represent another category of ADEs. It is important to distinguish pseudoallergic reactions from true allergies, as a misdiagnosis may result in unnecessary avoidance of certain medications. Pseudoallergic reactions (Table 6) are non-immune-mediated and mimic allergic responses, typically triggered by the release of histamine or other mediators without the immune system's involvement. For instance, itching or flushing following opioid use is a typical example of this phenomenon (Zhang et al., 2017). These effects can also include cardiovascular or pulmonary symptoms, as seen after the rapid administration of drugs dissolved in a propylene glycol vehicle (Mali, 2012).

Drug fever or hyperpyrexia is also categorized under pseudoallergic effects (Someko et al., 2024). Hyperpyrexia induced by aspirin is thought to result from the uncoupling of oxidative phosphorylation at the cellular level due to the action of salicylate (Krause et al., 1992). Certain antibiotics, like penicillins or cephalosporins, can induce drug fever through mechanisms unrelated to allergic reactions (Pichichero & Zagursky, 2014). In the context of vancomycin and opioids, pseudoallergic symptoms like itching or flushing can occur due to histamine release (Baldo, 2023). Patients might mistakenly believe they have a true allergy, resulting in anxiety regarding the use of effective pain management options. Pseudoallergic effects are also considered as a category of ADEs.

Table 6: *Overview of Allergic and Pseudoallergic Effects.*

Category	Description	Examples	Key Points
Allergic Effects	Hypersensitive immune responses to a drug, ranging from mild (e.g., rashes) to severe (e.g., anaphylaxis).	- Penicillin allergy: mild rashes to anaphylaxis - Cross-sensitivity: Penicillins and cephalosporins due to shared β-lactam structure - Sulfonamides: reactions with sulfonylureas or diuretics.	- Important for prescribing practices to avoid severe outcomes. - Cross-reactivity highlights the need for cautious drug selection in known allergic patients. - Comprise a significant portion of ADEs
Pseudoallergic Effects	Non-immune-mediated reactions mimic allergic responses, often involving histamine release or other mediators.	- Itching/flushing after opioids - Drug fever from penicillins or cephalosporins Hyperpyrexia from aspirin due to uncoupling of oxidative phosphorylation	- Differentiation from true allergies is crucial to avoid unnecessary drug avoidance. - Misdiagnosis can lead to anxiety and limited treatment options. - Histamine-related symptoms are common triggers.

Idiosyncratic Effects

Idiosyncratic effects refer to unpredictable and atypical reactions to a medication that occurs in a small number of individuals (Kaplowitz, 2005). These effects are not dose-dependent and may arise due to genetic or environmental factors, emphasizing the complexities of individual medication responses. Such reactions often result from genetic variations that impact drug metabolism or immune responses. For example, polymorphisms in genes encoding drug-metabolizing enzymes or drug transporters can cause atypical reactions to standard drug doses. Additionally, rare metabolic disorders can disrupt normal drug metabolism, leading to unexpected ADEs (Roth et al., 2003).

Severe skin reactions triggered by drugs such as sulfonamides, allopurinol, and anticonvulsants are examples of drug idiosyncrasies. These reactions occur in specific individuals due to unique genetic factors, leading to unpredictable and uncommon responses to these medications (Del Pozzo-Magaña & Liy-Wong, 2024). An illustrative example is the severe reactions some individuals experience with carbamazepine, such as Stevens-Johnson syndrome (SJS), which occurs unpredictably and is not dose-dependent, emphasizing the need for improved screening and personalized medicine approaches. SJS and toxic epidermal necrolysis (TEN) are severe, life-threatening reactions that involve widespread skin peeling and mucosal damage. These conditions can be triggered by medications and are characterized by blistering and detachment of the skin, leading to significant morbidity and potential complications (Fernando, 2016), and their occurrence is thought to be related to genetic predispositions, such as HLA-B1502 in individuals of Asian descent (Belver et al., 2016).

Drug-induced liver Injury can occur with various medications, including acetaminophen and certain antibiotics such as chloramphenicol, which are also conceded as an idiosyncratic reaction (Katarey & Verma, 2016). Another example of idiosyncratic reactions is aplastic anemia, where the bone marrow fails to produce adequate blood cells. It can be an idiosyncratic reaction to chloramphenicol or specific antiepileptics such as lamotrigine drugs (Tembe-Fokunang et al., 2022). Table 7 summarizes the drug idiosyncratic effects.

Table 7: *Overview of drugs idiosyncratic Effects.*

Aspect	Description	Examples	Key Points
Underlying Mechanisms	Often caused by genetic variations affecting drug metabolism or immune response. Rare metabolic disorders may also disrupt normal drug metabolism, leading to unexpected ADEs.	Polymorphisms in genes encoding drug-metabolizing enzymes or drug transporters.	Genetic predispositions require advanced screening techniques to prevent ADEs.
Skin Reactions	Severe idiosyncratic reactions manifest as conditions like Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).	- Drugs: Sulfonamides, allopurinol, anticonvulsants. - Example: Carbamazepine-induced SJS and TEN, especially in individuals with HLA-B1502	Screening for genetics is crucial

Population at Risk

Populations at risk are individuals who are particularly susceptible to ADEs due to variability in physiology, pharmacokinetic, and pharmacodynamic aspects. These vulnerabilities may arise from age, genetic predispositions, comorbidities, or concurrent medication use, all of which can alter drug metabolism, sensitivity, or clearance. (Delafuente, 2008). Herein, they are discussed.

Children face an increased likelihood of experiencing ADEs because of their growing physiological systems and fluctuating metabolic rates. Their drug processing differs from adults, impacting how well medications work and their safety (Alghamdi, 2021). For instance, pediatric dosing typically varies significantly from adult recommendations, requiring meticulous adjustments based on factors like body weight, organ development, and enzyme activity (Bartelink et al., 2006). Moreover, children's distinct developmental phases can result in varied medication responses, emphasizing the need for healthcare professionals to monitor them closely (Al-mutairi et al., 2024).

Elderly patients often encounter polypharmacy, elevating the likelihood of drug interactions and ADEs (Wolff et al., 2021). Physiological changes associated with aging, such as modifications in pharmacokinetics, further heighten their vulnerability to ADEs (Spina & Scordo, 2002). For instance, diminished renal and hepatic function in older adults can result in drug accumulation, increasing the risk of toxicity, especially if dosages are not adequately tailored (Soraci et al., 2023). Multiple comorbidities frequently complicate medication regimens, requiring thorough assessment and continuous monitoring to minimize risks (Boyd et al., 2005).

Obese or overweight individuals represent another at-risk population, as obesity can markedly influence drug pharmacokinetics, leading to alterations in medication volume of distribution and metabolism (Morrish et al., 2011). Obese individuals often require tailored dosing strategies, as conventional regimens may fail to account for physiological changes associated with increased body weight (Griggs et al., 2021). Furthermore, overweight and obesity can worsen comorbid conditions like diabetes and hypertension, which in turn affect drug response and elevate the risk of ADEs (Tuccinardi et al., 2024). This necessitates a tailored approach to medication management in overweight and obese populations to ensure safety and efficacy.

Underweight or emaciated individuals may have changes in drug absorption, distribution, and elimination, increasing their susceptibility to ADEs (Tipping, 2006). A reduced body mass can influence the volume of distribution for lipophilic drugs, potentially resulting in elevated plasma concentrations and a higher risk of toxicity (Gouju & Legeay, 2023).

Additionally, the physiological changes linked to being underweight, including alterations in metabolic rate and organ function, can complicate drug therapy and increase the necessity for vigilant monitoring of these patients (Pan et al., 2016).

Pregnant women are at a heightened risk of ADEs due to the significant physiological changes that take place during pregnancy (Soma-Pillay et al., 2016), such as alterations in drug metabolism, renal clearance, and an increase in plasma volume (Parekh et al., 2011).

These physiological changes can affect drug levels and efficacy, potentially posing risks to both the mother and fetal development. Certain medications may cross the placental barrier, impacting fetal growth and development (Griffiths & Campbell, 2015) This underscores the importance of healthcare providers carefully evaluating the risk-benefit profile of medications when prescribing to pregnant women, ensuring the safety of both the mother and fetus (Alkhalifah et al., 2023).

Patients with liver or kidney dysfunction face an increased risk of ADEs due to impaired drug metabolism and excretion (Franz, 2012). Hepatic impairment can reduce drug clearance, elevating the risk of drug-induced hepatotoxicity (Pandit et al., 2012). Likewise, renal dysfunction can lead to drug accumulation and potential toxicity as the body struggles to eliminate drugs efficiently (Pazhayattil & Shirali, 2014). This population requires careful attention in drug management, with dosing adjustments and vigilant monitoring essential to minimize the risk of ADEs.

Medications not specifically labeled for certain populations, such as children, the elderly, pregnant individuals, or those with specific medical conditions, can present increased risks (Van Norman, 2023). These populations often have distinct physiological and metabolic characteristics that can affect how drugs are processed in the body. For example, the pharmacokinetics and pharmacodynamics of a medication can differ significantly between adults and children, resulting in variations in both efficacy and safety (van den Anker et al., 2018). The absence of sufficient clinical trials in these populations means healthcare providers may lack the necessary information for informed prescribing decisions, potentially leading to ADEs that could have been foreseen with more comprehensive data. Moreover, off-label use of medications can complicate treatment further, raising the risk of ADEs (Sutphin et al., 2020).

Drugs with a narrow therapeutic index (NTI) have a limited margin between their therapeutic and toxic doses, making their clinical management particularly challenging (Habet, 2021). These medications require meticulous monitoring to ensure patients remain within the therapeutic range (Tamargo et al., 2015).

For example, medications like warfarin, digoxin, and lithium require regular blood tests to track their levels, as even slight fluctuations can result in serious toxicities or therapeutic failures. The risks associated with NTI drugs are elevated in populations such as the elderly or individuals with renal or hepatic impairment, where drug clearance may be affected (Jcs et al., 2017). As a result, CPs and other healthcare providers must remain vigilant in adjusting dosages and closely monitoring patient responses to minimize the risk of ADEs (Sonnexa et al., 2004).

Inappropriate prescribing or trivial use of drugs also may lead to ADEs (Hamilton et al., 2009). The prescription of medications for indications that are not supported by solid clinical evidence or for trivial symptoms that may resolve on their own can lead to unnecessary ADEs (Bano et al., 2012). For instance, using antibiotics to treat viral infections is a prevalent issue that exposes patients to unnecessary risks while contributing to antibiotic resistance (Chinemerem Nwobodo et al., 2022). Furthermore, medications prescribed for mild or self-limiting conditions, when non-pharmacological interventions may suffice, can lead to unnecessary side effects (Narang et al., 2023). This emphasizes the importance of evidence-based prescribing and the need for healthcare professionals to carefully assess the necessity of medications carefully, ensuring patients receive appropriate treatment without the risk of preventable ADEs.

Failure to establish clear therapeutic goals or endpoints is another key contributor to ADEs. Setting well-defined goals and endpoints is essential for effective treatment and ensuring that interventions are aligned with desired outcomes (Salgar et al., 2024). Without defined objectives, healthcare providers may struggle to assess a medication's effectiveness, potentially leading to the continued use of ineffective treatments. Clear therapeutic goals guide clinical decisions and enhance communication between providers and patients, promoting patient involvement in their care (Robert Cronin Yung Peng, Rose Khavari & Kate Shannon ., 2016). Moreover, when patients understand the intended outcomes of their therapy, they are more likely to adhere to treatment regimens and report any SEs they experience (Cheng & Wang, 2010). Therefore, collaborative goal-setting is essential to enhance treatment outcomes and minimize the risk of ADEs.

Polypharmacy, the concurrent use of multiple medications, significantly raises the risk of drug interactions and the accumulation of ADEs (Edwards & Aronson, 2000). This issue is especially common among elderly patients or those with multiple chronic conditions, where complex treatment regimens make managing and monitoring potential interactions challenging. Each additional medication increases the risk of interactions and complicates adherence to the prescribed treatment plan (Rieckert et al., 2018).

CP's role in the management of ADEs

CPs are essential in addressing adverse drug events (ADEs), which can significantly affect patient adherence and overall health outcomes (Rotta et al., 2015). They play a crucial role in adjusting drug regimens and monitoring potential ADEs, offering patient-specific recommendations to ensure safety and efficacy (Dunn et al., 2015). Furthermore, CPs are pivotal in reviewing medication lists for potential interactions, providing guidance for necessary adjustments, and ensuring that treatment plans are simple and effective (Carlqvist et al., 2024).

While providing pharmacotherapeutic services, CPs must carefully assess each patient's likelihood of adverse drug events (ADEs), considering their unique health status, comorbidities, and concurrent medications (Olea et al., 2018). By understanding the specific

needs of different patient populations, CPs can tailor their interventions to minimize risks and optimize therapeutic outcomes (Yoshimura et al., 2022). Their strategies include various interventions, such as adjusting dosages to maximize therapeutic effects while minimizing ADEs. When a medication leads to intolerable side effects, CPs recommend alternative therapies that align with the patient's treatment goals, ensuring a more effective and well-tolerated treatment plan (Bishop et al., 2024). Failure to weigh the benefits versus risks of therapy may also lead to ADEs. The decision to initiate, continue, or modify therapy should involve carefully assessing the benefits versus the risks associated with the medication (Hong et al., 2021). This assessment is critical in ensuring that the potential benefits of a treatment outweigh its risks, especially for patients with complex health conditions or those on multiple medications (Riordan et al., 2016). Factors such as the patient's overall health status, the potential for ADEs, and the likelihood of achieving therapeutic goals must be carefully considered. Involving patients in this process promotes shared decision-making, empowers them to take an active role in their treatment, and improves adherence and satisfaction while minimizing risks (Krist et al., 2017).

Moreover, CPs offer thorough patient education to ensure individuals comprehend their medications, potential side effects, and the importance of adhering to therapy (Saseen et al., 2017). By effectively managing these effects, CPs improve patient safety and therapeutic outcomes, ensuring that the benefits of medication use outweigh the risks.

To prevent and manage toxic effects, CPs closely monitor drug levels, particularly for patients on high-risk medications. They adjust dosages as needed and educate patients about potential drug interactions that could lead to ADEs (Flores et al., 2024). Special attention is paid to patients with preexisting renal conditions, as these individuals may be more vulnerable to nephrotoxic drugs (Fusco et al., 2016). CPs aim to avoid such drugs whenever possible and ensure safe dosing practices (Matzke et al., 2011). Additionally, they are vigilant in addressing issues of neurotoxicity, which can lead to serious symptoms like neuropathy or cognitive disturbances, thus safeguarding patients' neurological health (Bilge, 2016).

In handling idiosyncratic drug reactions, CPs perform genetic tests to identify patients who may experience unusual reactions to certain medications. By customizing drug treatments based on genetic information and working with other healthcare providers, they develop personalized treatment strategies that help reduce the risks linked to these reactions (A.Mshiemish, 2017). This tailored approach improves patient safety and supports more effective medication therapy, especially for individuals with distinct genetic traits (Marques et al., 2024).

They thoroughly assess the suitability of off-label drug use and explore well-researched alternatives that are properly labeled for particular patient groups (Petkova et al., 2023). This is especially crucial for patients using medications with an NTI, as there is a small margin for dosing error. For these individuals, clinical pharmacists (CPs) perform regular therapeutic

drug monitoring, adjust doses as needed, and offer focused patient education to avoid toxicity while maintaining effective treatment (Kang & Lee, 2009).

Finally, clinical pharmacists (CPs) must continually assess the risk-benefit balance of each medication, especially for patients with complex health issues or those undergoing high-risk treatments (Peloso et al., 2013). This thorough evaluation is crucial for making informed clinical decisions, ensuring patients receive the most effective and safest medication regimen suited to their needs.

CONCLUSION AND RECOMMENDATIONS

ADEs encompass various issues, such as variations in pharmacological effects, side effects, allergic reactions, drug-induced organ damage, and idiosyncratic responses. Misunderstandings and inconsistencies in classifying pharmacologic and side effects can significantly influence clinical decision-making and patient outcomes. Clarifying these misconceptions with clear definitions and standardized training is essential for improving drug therapy. Healthcare providers, especially CPs, are essential in identifying and managing ADEs, ensuring adherence to clinical definitions, and minimizing risks. The following recommendations are made to improve healthcare quality and patient outcomes: (1) Enhance knowledge and education by offering continuous training on drug effect classifications and ADE management. This helps healthcare professionals, particularly CPs, stay informed about new safety information, emerging risks, and how to apply clinical definitions accurately, (2) Implement risk stratification through regular identification of high-risk patient groups and tailoring pharmacotherapy to prevent ADEs and improve treatment outcomes, (3) Promote multidisciplinary collaboration by Encouraging strong cooperation between CPs, physicians, nurses, and other healthcare professionals to ensure comprehensive ADE management and shared understanding of drug effects and (4) Improve patient understanding by educating patients on their medications, potential side effects, and the importance of adherence to treatment plans. Clear communication about the differences between pharmacologic and side effects can help empower patients and improve safety. By adopting these strategies, healthcare teams can better align clinical practice with standardized definitions, manage ADEs more effectively, and achieve optimal therapeutic outcomes.

Conflict of Interest: The author(s) declared no conflict of interest.

REFERENCES

A.Mshiemish, B. (2017). Role of the Clinical Pharmacist in Reducing Preventable Adverse Drug Events. *Iraqi Journal of Pharmaceutical Sciences (P-ISSN 1683 - 3597 E-ISSN 2521 - 3512)*, *20*(2), 85–90. https://doi.org/10.31351/vol20iss2pp85-90

Al-mutairi, A. A. T., Al-mutlaq, K. F. A., Saad, A., Alruwaili, S., Falah, W., & Alenezi, N. (2024). *A Comprehensive Review of Medication Errors in Pediatrics and Adults : Types , Causes , And the Role of The Pharmacist in Prevention*. *7*.

Alghamdi, A. A. M. (2021). *Medication Safety in Neonatal and C hildren ' s Intensive Care A thesis submitted to the University of Manchester for the degree of Doctor of Philosophy in the Faculty of Biology , Medicine and Health Anwar Ali M Alghamdi Division of Pharmacy and Optometr*. 278.

Alkhalifah, B. F., Alessa, R. F., Alhumaidi, R. M., Sundus, A., Abdulsalim, S., Jabeen, A., & Ismail, W. I. (2023). Attitudes and Practices of Community Pharmacists toward the Risk of Medication Use by Pregnant Women: A Cross-Sectional Study in the Qassim Region, Saudi Arabia. *Journal of Hunan University Natural Sciences*, *50*(11). https://doi.org/10.55463/issn.1674-2974.50.11.7

Alqurbi, M., & Atiah, M. (2020). The role of clinical pharmacists in reducing adverse drug reactions. *International Journal of Medicine in Developing Countries*, *4*(1), 236–239. https://doi.org/10.24911/ijmdc.51-1570008849

Alsultan, A., & Peloquin, C. A. (2014). Therapeutic drug monitoring in the treatment of tuberculosis: An update. *Drugs*, *74*(8), 839–854. https://doi.org/10.1007/s40265-014-0222-8

Azad, M. A., Nesar, A. J., & Ghafari, A. T. (2024). *Bibliometric Analysis of Pyrimidine Compounds with Anti-cancer Activity : Research Trends from 2015 to 2023*. *2*(3), 1–16.

Bailey, C., Peddie, D., Wickham, M. E., Badke, K., Small, S. S., Doyle-Waters, M. M., Balka, E., & Hohl, C. M. (2016). Adverse drug event reporting systems: a systematic review. *British Journal of Clinical Pharmacology*, 17–29. https://doi.org/10.1111/bcp.12944

Baldo, B. A. (2023). MRGPRX2, drug pseudoallergies, inflammatory diseases, mechanisms and distinguishing MRGPRX2- and IgE/FcεRI-mediated events. *British Journal of Clinical Pharmacology*, *89*(11), 3232–3246. https://doi.org/10.1111/bcp.15845

Bangwal, R., Bisht, S., Saklani, S., Garg, S., & Dhayani, M. (2020). Psychotic Disorders, Definition, Sign and Symptoms, Antipsychotic Drugs, Mechanism of Action, Pharmacokinetics & Pharmacodynamics with Side Effects & Adverse Drug Reactions: Updated Systematic Review Article. *Journal of Drug Delivery and Therapeutics*, *10*(1), 163–172. https://doi.org/10.22270/jddt.v10i1.3865

Bano, N., Najam, R., & Qazi, F. (2012). Irrational drug use based on self medication for some common clinical conditions in an educated population of Karachi. *Pakistan Journal of Medical Sciences*, *28*(3), 359–362.

Barnett, L. M. A., & Cummings, B. S. (2018). Nephrotoxicity and renal pathophysiology: A contemporary perspective. *Toxicological Sciences*, *164*(2), 379–390. https://doi.org/10.1093/toxsci/kfy159

Bartelink, I. H., Rademaker, C. M. A., Schobben, A. F. A. M., & Van Den Anker, J. N. (2006). Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations. *Clinical Pharmacokinetics*, *45*(11), 1077–1097. https://doi.org/10.2165/00003088-200645110-00003

Belver, M. T., Michavila, A., Bobolea, I., Feito, M., Bellón, T., & Quirce, S. (2016). Severe delayed skin reactions related to drugs in the paediatric age group: A review of the subject by way of three cases (Stevens-Johnson syndrome, toxic epidermal necrolysis and DRESS). *Allergologia et Immunopathologia*, *44*(1), 83–95. https://doi.org/10.1016/j.aller.2015.02.004

Bilge, S. (2016). We are IntechOpen , the world ' s leading publisher of Open Access books Built by scientists , for scientists TOP 1 %. In *Intech* (Vol. 11, Issue tourism, p. 13). https://www.intechopen.com/books/advanced-biometric-technologies/liveness-detection-in-biometrics

Bishop, J. R., Schneiderhan, M. E., Butler, T., Carpentier, R. M., Heins, K. R., & Formea, C. M. (2024). Pharmacogenomics to support mental health medication therapy management: Clinical practice considerations and a conceptual framework to enhance patient care. *JACCP Journal of the American College of Clinical Pharmacy*, *7*(2), 160–170. https://doi.org/10.1002/jac5.1892

Blenkinsopp, A., Paxton, P., & Blenkinsopp, J. (2008). Symptoms in the Pharmacy. In *Symptoms in the Pharmacy*. https://doi.org/10.1002/9781444300611

Bonilla-Jaime, H., Sánchez-Salcedo, J. A., Estevez-Cabrera, M. M., Molina-Jiménez, T., Cortes-Altamirano, J. L., & Alfaro-Rodríguez, A. (2021). Depression and Pain: Use of Antidepressants. *Current Neuropharmacology*, *20*(2), 384–402. https://doi.org/10.2174/1570159x19666210609161447

Boyd, C. M., Darer, J., Boult, C., Fried, L. P., Boult, L., & Wu, A. W. (2005). Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: Implications for pay for performance. *Jama*, *294*(6), 716–724. https://doi.org/10.1001/jama.294.6.716

Carlqvist, C., Ekstedt, M., & Lehnbom, E. C. (2024). Exploring the impact of pharmacist-supported medication reviews in dementia care: experiences of general practitioners and nurses. *BMC Geriatrics*, *24*(1), 1–10. https://doi.org/10.1186/s12877-024-05124-9

Casey, D. E. (1997). *Pharmacology to Side Effects yr ht a In*. 55–62.

Cerniglia, C. E., & Kotarski, S. (2005). Approaches in the safety evaluations of veterinary antimicrobial agents in food to determine the effects on the human intestinal microflora. *Journal of Veterinary Pharmacology and Therapeutics*, *28*(1), 3–20. https://doi.org/10.1111/j.1365-2885.2004.00595.x

Chaudhry, S. B., Veve, M. P., & Wagner, J. L. (2019). Cephalosporins: A Focus on Side Chains and β-Lactam Cross-Reactivity. *Pharmacy*, *7*(3), 103. https://doi.org/10.3390/pharmacy7030103

Cheng, W., & Wang, X. (2010). Evaluation of the joint use of accident count and accident reduction potential to identify hotspot. *Presented at 89th Annual Meeting of the Transportation Research Board, Washington, DC*, *40*(9), 794–811.

https://doi.org/10.1097/01.MLR.0000024612.61915.2D

Chinemerem Nwobodo, D., Ugwu, M. C., Oliseloke Anie, C., Al-Ouqaili, M. T. S., Chinedu Ikem, J., Victor Chigozie, U., & Saki, M. (2022). Antibiotic resistance: The challenges and some emerging strategies for tackling a global menace. *Journal of Clinical Laboratory Analysis*, *36*(9), 1–10. https://doi.org/10.1002/jcla.24655

Daly, A. K. (2013). Pharmacogenomics of adverse drug reactions. *Genome Medicine*, *5*(1), 1–12. https://doi.org/10.1186/gm409

Del Pozzo-Magaña, B. R., & Liy-Wong, C. (2024). Drugs and the skin: A concise review of cutaneous adverse drug reactions. *British Journal of Clinical Pharmacology*, *90*(8), 1838–1855. https://doi.org/10.1111/bcp.15490

Delafuente, J. C. (2008). Pharmacokinetic and pharmacodynamic alterations in the geriatric patient. *Consultant Pharmacist*, *23*(4), 324–334. https://doi.org/10.4140/TCP.n.2008.324

Due, A. (2023). What are side effects? *European Journal for Philosophy of Science*, *13*(1), 1–21. https://doi.org/10.1007/s13194-023-00519-8

Duffus, J. H., Nordberg, M., & Templeton, D. M. (2007). Glossary of terms used in toxicology, 2nd edition (IUPAC recommendations 2007). *Pure and Applied Chemistry*, *79*(7), 1153–1344. https://doi.org/10.1351/pac200779071153

Dunn, S. P., Birtcher, K. K., Beavers, C. J., Baker, W. L., Brouse, S. D., Page, R. L., Bittner, V., & Walsh, M. N. (2015). The Role of the Clinical Pharmacist in the Care of Patients with Cardiovascular Disease. *Journal of the American College of Cardiology*, *66*(19), 2129–2139. https://doi.org/10.1016/j.jacc.2015.09.025

Edwards, I. R., & Aronson, J. K. (2000). Adverse drug reactions: Definitions, diagnosis, and management. *Lancet*, *356*(9237), 1255–1259. https://doi.org/10.1016/S0140-6736(00)02799-9

Eichler, H., Abadie, E., Breckenridge, A., Flamion, B., Gustafsson, L. L., Leufkens, H., Rowland, M., Schneider, C. K., & Bloechl-daum, B. (2011). *Bridging the efficacy–effectiveness gap: a regulator's perspective on addressing variability of drug response*. *10*(July), 495–506.

Eliseeva, T. I., & Balabolkin, I. I. (2016). Drug allergic reactions: Current views (Review). *Sovremennye Tehnologii v Medicine*, *8*(1), 159–170. https://doi.org/10.17691/stm2016.8.1.22

Enemchukwu, E. A., Subak, L. L., & Markland, A. (2022). Barriers and facilitators to overactive bladder therapy adherence. *Neurourology and Urodynamics*, *41*(8), 1983–1992. https://doi.org/10.1002/nau.24936

Faucon, A.-L., Bobrie, G., & Clément, O. (2019). *Nephrotoxicity of iodinated contrast media: from pathophysiology to prevention strategies*.

Ferguson, M. A., & Waikar, S. S. (2012). Established and Emerging Markers of Kidney

Function. *Physiology & Behavior*, *176*(1), 139–148. https://doi.org/10.1373/clinchem.2011.167494.Established

Fernando, S. L. (2016). Severe Cutaneous Adverse Reactions. *Intech*, *11*(tourism), 13. https://www.intechopen.com/books/advanced-biometric-technologies/liveness-detection-in-biometrics

Fillmore, M. T., Mulvihill, L. E., & Vogel-Sprott, M. (1994). The expected drug and its expected effect interact to determine placebo responses to alcohol and caffeine. *Psychopharmacology*, *115*(3), 383–388. https://doi.org/10.1007/BF02245081

Flores, J., Flank, J., Polito, S., Dhillon, P., Pang, I., Ho, L., & Yee, K. W. L. (2024). Evaluation of voriconazole therapeutic drug monitoring in malignant hematology patients. *Journal of Oncology Pharmacy Practice*. https://doi.org/10.1177/10781552241284528

Fokunang, C. (2018). Overview of non-steroidal anti-inflammatory drugs (nsaids) in resource limited countries. *MOJ Toxicology*, *4*(1). https://doi.org/10.15406/mojt.2018.04.00081

Fragkas, N. (2020). *Immunological Investigations Into Naproxen-Induced Idiosyncratic Hepatotoxicity*.

Franz, C. C. (2012). *Drug-related Problems and Dosage Adjustment in Patients with Liver Disease*.

Fricke, C., & Voderholzer, U. (2023). Endocrinology of Underweight and Anorexia Nervosa. *Nutrients*, *15*(16), 1–13. https://doi.org/10.3390/nu15163509

Fritsch, P. O., & Sidoroff, A. (2000). *Drug-Induced Stevens-Johnson Syndrome / Toxic Epidermal Necrolysis*. *1*(6), 349–360.

Fusco, S., Garasto, S., Corsonello, A., Vena, S., Mari, V., Gareri, P., Ruotolo, G., Luciani, F., Roncone, A., Maggio, M., & Lattanzio, F. (2016). Medication-Induced Nephrotoxicity in Older Patients. *Current Drug Metabolism*, *17*(6), 608–625. https://doi.org/10.2174/1389200217666160406115959

Gabay, M., & Spencer, S. H. (2021). Drug Interactions: Scientific and Clinical Principles. *PSAP 2021 Book 3: Chronic Conditions and Public Health*, 7–28.

Gelberg, H., & States, U. (2020). *Pathophysiological Mechanisms of Gastrointestinal Toxicity*. *January*.

Giannitrapani, K. F., Glassman, P. A., Vang, D., McKelvey, J. C., Thomas Day, R., Dobscha, S. K., & Lorenz, K. A. (2018). Expanding the role of clinical pharmacists on interdisciplinary primary care teams for chronic pain and opioid management. *BMC Family Practice*, *19*(1), 1–9. https://doi.org/10.1186/s12875-018-0783-9

Giles, A., Foushee, J., Lantz, E., & Gumina, G. (2019). Sulfonamide Allergies. *Pharmacy*, *7*(3), 132. https://doi.org/10.3390/pharmacy7030132

Glauser, T. A. (2000). *Idiosyncratic Reactions: New Methods*. *41*, 16–29.

Gouju, J., & Legeay, S. (2023). Pharmacokinetics of obese adults: Not only an increase in weight. *Biomedicine and Pharmacotherapy*, *166*(June), 115281. https://doi.org/10.1016/j.biopha.2023.115281

Griffiths, S. K., & Campbell, J. P. (2015). Placental structure, function and drug transfer. *Continuing Education in Anaesthesia, Critical Care and Pain*, *15*(2), 84–89. https://doi.org/10.1093/bjaceaccp/mku013

Griggs, J. J., Bohlke, K., Balaban, E. P., Dignam, J. J., Hall, E. T., Harvey, R. D., Hecht, D. P., Klute, K. A., Morrison, V. A., Pini, T. M., Rosner, G. L., Runowicz, C. D., Shayne, M., Sparreboom, A., Turner, S., Zarwan, C., & Lyman, G. H. (2021). Appropriate systemic therapy dosing for obese adult patients with cancer: ASCO Guideline update. *Journal of Clinical Oncology*, *39*(18), 2037–2048. https://doi.org/10.1200/JCO.21.00471

Gunaydin, C., & Bilge, S. S. (2018). Effects of nonsteroidal anti-inflammatory drugs at the molecular level. *Eurasian Journal of Medicine*, *50*(2), 116–121. https://doi.org/10.5152/eurasianjmed.2018.0010

Habet, S. (2021). Narrow therapeutic index drugs: Clinical pharmacology perspective. *Journal of Pharmacy and Pharmacology*, *73*(10), 1285–1291. https://doi.org/10.1093/jpp/rgab102

Hacker, M. (2009). Adverse Drug Reactions. In *Pharmacology: Principles and Practice* (1st ed.). Elsevier Inc. https://doi.org/10.1016/B978-0-12-369521-5.00013-0

Hamilton, H. J., Gallagher, P. F., & O'Mahony, D. (2009). Inappropriate prescribing and adverse drug events in older people. *BMC Geriatrics*, *9*(1), 1–4. https://doi.org/10.1186/1471-2318-9-5

Hein, U. R., Chantraine-Hess, S., Worm, M., Zuberbier, T., & Henz, B. M. (1999). Evaluation of systemic provocation tests in patients with suspected allergic and pseudoallergic drug reactions. *Acta Dermato-Venereologica*, *79*(2), 139–142. https://doi.org/10.1080/00015599750011372

Heta, S., & Robo, I. (2018). The Side Effects of the Most Commonly Used Group of Antibiotics in Periodontal Treatments. *Medical Sciences (Basel, Switzerland)*, *6*(1), 1–6. https://doi.org/10.3390/medsci6010006

Hong, J., Ahn, S. Y., Lee, Y. J., Lee, J. H., Han, J. W., Kim, K. H., Yhim, H. Y., Nam, S. H., Kim, H. J., Song, J., Kim, S. H., Bang, S. M., Kim, J. S., Mun, Y. C., Bae, S. H., Kim, H. K., Jang, S., Park, R., Choi, H. S., … Oh, D. (2021). Updated recommendations for the treatment of venous thromboembolism. *Blood Research*, *56*(1), 6–16. https://doi.org/10.5045/br.2021.2020083

Iqubal, A., Ehtaishamul Haque, S., Sharma, S., Asif Ansari, M., Khan, V., & Kashif Iqubal, M. (2018). Clinical Updates on Drug-Induced Cardiotoxicity. *International Journal of*

Pharmaceutical Sciences and Research, *9*(1), 16. https://doi.org/10.13040/ijpsr.0975-8232.9(1).16-26

Jadhav, P. R., Goyal, S., & Dhavalshankh, G. (2024). *Comparative evaluation of liver function test in refractive psoriasis patients treated with tofacitinib and apremilast Comparative evaluation of liver function test in refractive psoriasis patients treated with tofacitinib and apremilast*. *October*. https://doi.org/10.18203/2394-6040.ijcmph20242885

Jcs, K. A., Jstdm, T. S., Atarashi, H., & Doki, K. (2017). *Guidelines for Therapeutic Drug Monitoring of Cardiovascular Drugs Clinical Use of Blood Drug Concentration Monitoring (JCS 2015) — Digest Version —*. *81*(April), 581–612. https://doi.org/10.1253/circj.CJ-66-0138

Johnson, K. K., Green, D. L., Rife, J. P., & Limon, L. (2005). Sulfonamide cross-reactivity: Fact or fiction? *Annals of Pharmacotherapy*, *39*(2), 290–301. https://doi.org/10.1345/aph.1E350

Kang, J. S., & Lee, M. H. (2009). Overview of therapeutic drug monitoring. *Korean Journal of Internal Medicine*, *24*(1), 1–10. https://doi.org/10.3904/kjim.2009.24.1.1

Kaplowitz, N. (2005). Idiosyncratic drug hepatotoxicity. *Nature Reviews Drug Discovery*, *4*(6), 489–499. https://doi.org/10.1038/nrd1750

Katarey, D., & Verma, S. (2016). Drug-induced liver injury. *Clinical Medicine, Journal of the Royal College of Physicians of London*, *16*(6), s104–s109. https://doi.org/10.7861/clinmedicine.16-6-s104

Kim, J., & Shin, M. (2014). An integrative model of multi-organ drug-induced toxicity prediction using gene-expression data. *BMC Bioinformatics*, *15*(16), 1–9. https://doi.org/10.1186/1471-2105-15-S16-S2

Kim, S. Y., Kim, M. H., & Cho, Y. J. (2018). Different clinical features of anaphylaxis according to cause and risk factors for severe reactions. *Allergology International*, *67*(1), 96–102. https://doi.org/10.1016/j.alit.2017.05.005

Krause, D. S., Wolf, B. A., & Shaw, L. M. (1992). Acute aspirin overdose: Mechanisms of toxicity. *Therapeutic Drug Monitoring*, *14*(6), 441–451. https://doi.org/10.1097/00007691-199212000-00001

Krist, A. H., Tong, S. T., Aycock, R. A., & Longo, D. R. (2017). Engaging patients in decision-making and behavior change to promote prevention. *Information Services and Use*, *37*(2), 105–122. https://doi.org/10.3233/ISU-170826

Luri, M., Leache, L., Gastaminza, G., Idoate, A., & Ortega, A. (2022). A systematic review of drug allergy alert systems. *International Journal of Medical Informatics*, *159*, 104673. https://doi.org/10.1016/j.ijmedinf.2021.104673

Mali, S. (2012). Anaphylaxis during the perioperative period. *Anesthesia: Essays and Researches*, *6*(2), 124. https://doi.org/10.4103/0259-1162.108286

Marques, L., Costa, B., Pereira, M., Silva, A., Santos, J., Saldanha, L., Silva, I., Magalhães, P., Schmidt, S., & Vale, N. (2024). Advancing Precision Medicine: A Review of Innovative In Silico Approaches for Drug Development, Clinical Pharmacology and Personalized Healthcare. *Pharmaceutics*, *16*(3). https://doi.org/10.3390/pharmaceutics16030332

Mattox, T. W. (2017). Cancer Cachexia: Cause, Diagnosis, and Treatment. *Nutrition in Clinical Practice*, *32*(5), 599–606. https://doi.org/10.1177/0884533617722986

Matzke, G. R., Aronoff, G. R., Atkinson, A. J., Bennett, W. M., Decker, B. S., Eckardt, K. U., Golper, T., Grabe, D. W., Kasiske, B., Keller, F., Kielstein, J. T., Mehta, R., Mueller, B. A., Pasko, D. A., Schaefer, F., Sica, D. A., Inker, L. A., Umans, J. G., & Murray, P. (2011). Drug dosing consideration in patients with acute and chronic kidney diseasea clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). *Kidney International*, *80*(11), 1122–1137. https://doi.org/10.1038/ki.2011.322

Mirakian, R., Leech, S. C., Krishna, M. T., Richter, A. G., Huber, P. A. J., Farooque, S., Khan, N., Pirmohamed, M., Clark, A. T., & Nasser, S. M. (2015). Management of allergy to penicillins and other beta-lactams. *Clinical and Experimental Allergy*, *45*(2), 300–327. https://doi.org/10.1111/cea.12468

Mladěnka, P., Applová, L., Patočka, J., Costa, V. M., Remiao, F., Pourová, J., Mladěnka, A., Karlíčková, J., Jahodář, L., Vopršalová, M., Varner, K. J., & Štěrba, M. (2018). Comprehensive review of cardiovascular toxicity of drugs and related agents. *Medicinal Research Reviews*, *38*(4), 1332–1403. https://doi.org/10.1002/med.21476

Möller, B., Pruijm, M., Adler, S., Scherer, A., Villiger, P. M., & Finckh, A. (2015). Chronic NSAID use and long-term decline of renal function in a prospective rheumatoid arthritis cohort study. *Annals of the Rheumatic Diseases*, *74*(4), 718–723. https://doi.org/10.1136/annrheumdis-2013-204078

Morrish, G. A., Pai, M. P., & Green, B. (2011). The effects of obesity on drug pharmacokinetics in humans. *Expert Opinion on Drug Metabolism and Toxicology*, *7*(6), 697–706. https://doi.org/10.1517/17425255.2011.570331

Mudd, T. W., Khalid, M., & Guddati, A. K. (2021). Cardiotoxicity of chemotherapy and targeted agents. *American Journal of Cancer Research*, *11*(4), 1132–1147. http://www.ncbi.nlm.nih.gov/pubmed/33948350%0Ahttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC8085845

Mudiyanse, B., King, C., Kumari, D., Daupadi, M., Mudiyanse, B., & Bond, D. W. (2024). *Comprehensive Review of Antihypertensive Medications: Mechanisms, Indications, Adverse Effects, and Monitoring COMPREHENSIVE REVIEW OF ANTIHYPERTENSIVE MEDICATIONS: MECHANISMS, INDICATIONS, ADVERSE EFFECTS, AND MONITORING Comprehensive Review of Antihyper*. *April*. https://www.researchgate.net/publication/380157069

Murru, A., Colom, F., Nivoli, A., Pacchiarotti, I., Valenti, M., & Vieta, E. (2011). When should

mood stabilizers be withdrawn due to lack of efficacy? Some methodological considerations. *European Psychiatry*, *26*(3), 183–186. https://doi.org/10.1016/j.eurpsy.2010.09.012

Musich, S., Wang, S. S., Slindee, L. B., Ruiz, J., & Yeh, C. S. (2020). Concurrent Use of Opioids with Other Central Nervous System-Active Medications among Older Adults. *Population Health Management*, *23*(4), 286–296. https://doi.org/10.1089/pop.2019.0128

Narang, P., Garg, V., & Sharma, A. (2023). Regulatory, safety and economic considerations of over-the-counter medicines in the Indian population. *Discover Health Systems*, *2*(1). https://doi.org/10.1007/s44250-023-00032-y

Nash, D. T. (1990). Alpha-adrenergic blockers: Mechanism of action, blood pressure control, and effects on lipoprotein metabolism. *Clinical Cardiology*, *13*(11), 764–772. https://doi.org/10.1002/clc.4960131104

Natalia M. Jasiak-Panek, Kevin T. Le, Thomas Moran, Mudahar, and S. (2019). Allergy and Sleep: Basic Principles and Clinical Practice. In *Allergy and Sleep: Basic Principles and Clinical Practice* (Issue June, pp. 1–463). https://doi.org/10.1007/978-3-030-14738-9

Olea, A., Grochowski, J., Luetkemeyer, A., Robb, V., & Saberi, P. (2018). Role of a clinical pharmacist as part of a multidisciplinary care team in the treatment of HCV in patients living with HIV/HCV coinfection. *Integrated Pharmacy Research and Practice*, *Volume 7*, 105–111. https://doi.org/10.2147/iprp.s169282

Oruch, R., Elderbi, M. A., Khattab, H. A., Pryme, I. F., & Lund, A. (2014). Lithium: A review of pharmacology, clinical uses, and toxicity. *European Journal of Pharmacology*, *740*(June), 464–473. https://doi.org/10.1016/j.ejphar.2014.06.042

Osterhoudt, K. C., & Penning, and T. M. (2018). Drug Toxicity and Poisoning. In *Pharmacology and Physiology for Anesthesia: Foundations and Clinical Application* (pp. 613–628). https://doi.org/10.1016/B978-0-323-48110-6.00030-2

P. Dooley, T. (2015). Treating Anxiety with either Beta Blockers or Antiemetic Antimuscarinic Drugs: A Review. *Mental Health in Family Medicine*, *11*(02). https://doi.org/10.25149/1756-8358.1102013

P Sharma, O. (2014). Clinical Biochemistry of Hepatotoxicity. *Journal of Clinical Toxicology*, *04*(01). https://doi.org/10.4172/2161-0495.s4-001

Pan, S. D., Zhu, L. L., Chen, M., Xia, P., & Zhou, Q. (2016). Weight-based dosing in medication use: What should we know? *Patient Preference and Adherence*, *10*, 549–560. https://doi.org/10.2147/PPA.S103156

Pandit, A., Sachdeva, T., & Bafna, P. (2012). Drug-induced hepatotoxicity: A review. *Journal of Applied Pharmaceutical Science*, *2*(5), 233–243. https://doi.org/10.7324/JAPS.2012.2541

Parekh, A., Fadiran, E. O., Uhl, K., & Throckmorton, D. C. (2011). Adverse effects in women:

Implications for drug development and regulatory policies. *Expert Review of Clinical Pharmacology*, *4*(4), 453–466. https://doi.org/10.1586/ecp.11.29

Patrignani, P., Tacconelli, S., Bruno, A., Sostres, C., & Lanas, A. (2011). Managing the adverse effects of nonsteroidal anti-inflammatory drugs. *Expert Review of Clinical Pharmacology*, *4*(5), 605–621. https://doi.org/10.1586/ecp.11.36

Pazhayattil, G. S., & Shirali, A. C. (2014). Drug-induced impairment of renal function. *International Journal of Nephrology and Renovascular Disease*, *7*, 457–468. https://doi.org/10.2147/IJNRD.S39747

Peloso, C., Baylatry, M.-T., Elefant, E., Fernandez, C., Joly, A.-C., & Isnard, F. (2013). 41st ESCP symposium on clinical pharmacy: personalised and safe therapy. *International Journal of Clinical Pharmacy*, *35*(5), 866–1019. https://doi.org/10.1007/s11096-013-9801-0

Petkova, V., Georgieva, D., Dimitrov, M., & Nikolova, I. (2023). Off-Label Prescribing in Pediatric Population—Literature Review for 2012–2022. *Pharmaceutics*, *15*(12), 1–20. https://doi.org/10.3390/pharmaceutics15122652

Pichichero, M. E., & Zagursky, R. (2014). Penicillin and Cephalosporin allergy. *Annals of Allergy, Asthma and Immunology*, *112*(5), 404–412. https://doi.org/10.1016/j.anai.2014.02.005

Pichler, W. J. (2006). Adverse side-effects to biological agents. *Allergy: European Journal of Allergy and Clinical Immunology*, *61*(8), 912–920. https://doi.org/10.1111/j.1398-9995.2006.01058.x

Pichler, W. J. (2019). Immune pathomechanism and classification of drug hypersensitivity. *Allergy: European Journal of Allergy and Clinical Immunology*, *74*(8), 1457–1471. https://doi.org/10.1111/all.13765

Pinky, Gupta, S., Krishnakumar, V., Sharma, Y., Dinda, A. K., & Mohanty, S. (2021). Mesenchymal Stem Cell Derived Exosomes: a Nano Platform for Therapeutics and Drug Delivery in Combating COVID-19. *Stem Cell Reviews and Reports*, *17*(1), 33–43. https://doi.org/10.1007/s12015-020-10002-z

Pusztaszeri, M. P., Genta, R. M., & Cryer, B. L. (2007). Drug-induced injury in the gastrointestinal tract: Clinical and pathologic considerations. *Nature Clinical Practice Gastroenterology and Hepatology*, *4*(8), 442–453. https://doi.org/10.1038/ncpgasthep0896

Raihan, R., Wafa, A., Zhakfar, A. M., & Sudhakar CK. (2024). Oral Disintegrating Films: A Review. *Journal of Natural Science Review*, *2*(2), 60–74. https://doi.org/10.62810/jnsr.v2i2.42

Rawlins, M. D. (1981). *Clinical pharmacology: Adverse reactions to drugs*. *282*(March), 974–976.

Reinert, T., Baldotto, C. S. da R., Nunes, F. A. P., & Scheliga, A. A. de S. (2013). Bleomycin-Induced Lung Injury. *Journal of Cancer Research*, *2013*, 1–9. https://doi.org/10.1155/2013/480608

Rieckert, A., Trampisch, U. S., Klaaßen-Mielke, R., Drewelow, E., Esmail, A., Johansson, T., Keller, S., Kunnamo, I., Löffler, C., Mäkinen, J., Piccoliori, G., Vögele, A., & Sönnichsen, A. (2018). Polypharmacy in older patients with chronic diseases: A cross-sectional analysis of factors associated with excessive polypharmacy. *BMC Family Practice*, *19*(1), 1–9. https://doi.org/10.1186/s12875-018-0795-5

Riordan, D. O., Walsh, K. A., Galvin, R., Sinnott, C., Kearney, P. M., & Byrne, S. (2016). The effect of pharmacist-led interventions in optimising prescribing in older adults in primary care: A systematic review. *SAGE Open Medicine*, *4*. https://doi.org/10.1177/2050312116652568

Robert Cronin Yung Peng, Rose Khavari, N. D., & Kate Shannon ., G. O. D. P. J. S. J. M. C. F. R. N. (2016). Use of Functional Assessment to Define Therapeutic Goals and Treatment. *Physiology & Behavior*, *176*(1), 139–148. https://doi.org/10.1111/jgs.15975.Use

Rohilla, A., & Yadav, S. (2013). Adverse drug reactions: An Overview. *International Journal of Pharmacological Research*, *3*(1), 10–12.

Rose, M. A., & Kam, P. C. A. (2002). Gabapentin: Pharmacology and its use in pain management. *Anaesthesia*, *57*(5), 451–462. https://doi.org/10.1046/j.0003-2409.2001.02399.x

Roth, R. A., Luyendyk, J. P., Maddox, J. F., & Ganey, P. E. (2003). Inflammation and drug idiosyncrasy - Is there a connection? *Journal of Pharmacology and Experimental Therapeutics*, *307*(1), 1–8. https://doi.org/10.1124/jpet.102.041624

Rotta, I., Salgado, T. M., Silva, M. L., Correr, C. J., & Fernandez-Llimos, F. (2015). Effectiveness of clinical pharmacy services: an overview of systematic reviews (2000–2010). *International Journal of Clinical Pharmacy*, *37*(5), 687–697. https://doi.org/10.1007/s11096-015-0137-9

Routledge, P. A. (2003). Adverse Drug Reactions and Interactions: Mechanisms, Risk Factors, Detection, Management and Prevention. In *Stephens' Detection of New Adverse Drug Reactions*. https://doi.org/10.1002/0470014199.ch2

Sacco, S., Braschinsky, M., Ducros, A., Lampl, C., Little, P., Van Den Brink, A. M., Pozo-Rosich, P., Reuter, U., Del Rio, M. S., Sinclair, A. J., Sinclair, A. J., Katsarava, Z., Katsarava, Z., Katsarava, Z., Katsarava, Z., & Martelletti, P. (2020). European headache federation consensus on the definition of resistant and refractory migraine. *Journal of Headache and Pain*, *21*(1), 1–13. https://doi.org/10.1186/s10194-020-01130-5

Sahilu, T., Getachew, M., Melaku, T., & Sheleme, T. (2020). Adverse Drug Events and Contributing Factors Among Hospitalized Adult Patients at Jimma Medical Center,

Southwest Ethiopia: A Prospective Observational Study. *Current Therapeutic Research - Clinical and Experimental*, *93*. https://doi.org/10.1016/j.curtheres.2020.100611

Salgar, J. B., Bais, S. K., & Yeldi, B. V. (2024). *THE SAFETY AND EFFICACY OF ATROVASTATIN IN EARLY*. *January*. https://doi.org/10.20959/wjpr20241-30731

Saltiel, P. F., & Silvershein, D. I. (2015). Major depressive disorder: Mechanism-based prescribing for personalized medicine. *Neuropsychiatric Disease and Treatment*, *11*, 875–888. https://doi.org/10.2147/NDT.S73261

Saseen, J. J., Ripley, T. L., Bondi, D., Burke, J. M., Cohen, L. J., McBane, S., McConnell, K. J., Sackey, B., Sanoski, C., Simonyan, A., Taylor, J., & Vande Griend, J. P. (2017). ACCP Clinical Pharmacist Competencies. *Pharmacotherapy*, *37*(5), 630–636. https://doi.org/10.1002/phar.1923

Schacht, J., Talaska, A. E., & Rybak, L. P. (2012). Cisplatin and Aminoglycoside Antibiotics: Hearing Loss and Its Prevention. *Anatomical Record*, *295*(11), 1837–1850. https://doi.org/10.1002/ar.22578

Schatz, S. N., & Weber, R. J. (2015). Adverse drug reactions. *Lancet*, *357*(9255), 561. https://doi.org/10.1016/S0140-6736(05)71713-X

Shahzad, B., Mughal, M. N., Tanveer, M., Gupta, D., & Abbas, G. (2017). Is lithium biologically an important or toxic element to living organisms? An overview. *Environmental Science and Pollution Research*, *24*(1), 103–115. https://doi.org/10.1007/s11356-016-7898-0

Sherman, W. B. (1971). Drug allergy. *Southern Medical Journal*, *64*(1), 22–26. https://doi.org/10.1097/00007611-197101000-00006

Singh, D., Cho, W. C., & Upadhyay, G. (2016). Drug-induced liver toxicity and prevention by herbal antioxidants: An Overview. *Frontiers in Physiology*, *6*(JAN), 1–18. https://doi.org/10.3389/fphys.2015.00363

Snyder, H. (2019). Literature review as a research methodology: An overview and guidelines. *Journal of Business Research*, *104*(July), 333–339. https://doi.org/10.1016/j.jbusres.2019.07.039

Soma-Pillay, P., Nelson-Piercy, C., Tolppanen, H., & Mebazaa, A. (2016). Physiological changes in pregnancy. *Cardiovascular Journal of Africa*, *27*(2), 89–94. https://doi.org/10.5830/CVJA-2016-021

Someko, H., Okazaki, Y., Kuniyoshi, Y., Yoshida, A., Baba, K., Ijiri, A., & Tsujimoto, Y. (2024). Prevalence of Drug Fever among Cases of Nosocomial Fever: A Systematic Review and Meta-analysis. *Internal Medicine*, *63*(8), 1067–1074. https://doi.org/10.2169/internalmedicine.2322-23

Sonnexa, K., Alleemuddera, H., & Chena, L. (2004). Clinical pharmacy and pharmacy practice. *Lancet*, *1*(1), 2017. http://onlinelibrary.wiley.com/doi/10.1111/ijpp.12146/full

Soraci, L., Cherubini, A., Paoletti, L., Filippelli, G., Luciani, F., Laganà, P., Gambuzza, M. E., Filicetti, E., Corsonello, A., & Lattanzio, F. (2023). Safety and Tolerability of Antimicrobial Agents in the Older Patient. *Drugs and Aging*, *40*(6), 499–526. https://doi.org/10.1007/s40266-023-01019-3

Spencer, P. S., & Lein, P. J. (2023). Neurotoxicity. *Encyclopedia of Toxicology, Fourth Edition: Volume 1-9*, *6*, V6-727-V6-740. https://doi.org/10.1016/B978-0-12-824315-2.00548-0

Spina, E., & Scordo, M. G. (2002). Clinically significant drug interactions with antidepressants in the elderly. *Drugs and Aging*, *19*(4), 299–320. https://doi.org/10.2165/00002512-200219040-00004

Staff, N. P., Cavaletti, G., Islam, B., Lustberg, M., Psimaras, D., & Tamburin, S. (2019). Platinum-induced peripheral neurotoxicity: From pathogenesis to treatment. *Journal of the Peripheral Nervous System*, *24*(S2), S26–S39. https://doi.org/10.1111/jns.12335

Steinman, M. A., Handler, S. M., Gurwitz, J. H., Schiff, G. D., & Covinsky, K. E. (2011). Beyond the prescription: Medication monitoring and adverse drug events in older adults. *Journal of the American Geriatrics Society*, *59*(8), 1513–1520. https://doi.org/10.1111/j.1532-5415.2011.03500.x

Sutphin, C., Lee, K., Yepes, A. J., Uzuner, Ö., & McInnes, B. T. (2020). Adverse drug event detection using reason assignments in FDA drug labels. *Journal of Biomedical Informatics*, *110*(September), 103552. https://doi.org/10.1016/j.jbi.2020.103552

Tamargo, J., Le Heuzey, J. Y., & Mabo, P. (2015). Narrow therapeutic index drugs: A clinical pharmacological consideration to flecainide. *European Journal of Clinical Pharmacology*, *71*(5), 549–567. https://doi.org/10.1007/s00228-015-1832-0

Tembe-Fokunang, E., Djuidje Nganoue, M., Edwige, V., Mayoudom, T., Aghem, F. K., Sack Françoise, N., Michel, T., Claude, T. T., Samuel, N., Essi, M. J., Mbanya, D., Abena, M. T., Ondoua, O., & Fokunang, C. N. (2022). The Scope of Aplastic Anaemia: Etiology, Pathophysiology, Pharmacotherapy and Pharmacoeconomic Impact in Clinical Patient Management. *International Journal of Research and Reports in Hematology*, *5*(2), 243–260. https://journalijr2h.com/index.php/IJR2H/article/view/72

Tewabe, A., Abate, A., Tamrie, M., Seyfu, A., & Siraj, E. A. (2021). Targeted drug delivery — from magic bullet to nanomedicine: Principles, challenges, and future perspectives. *Journal of Multidisciplinary Healthcare*, *14*, 1711–1724. https://doi.org/10.2147/JMDH.S313968

Tipping, B. N. (2006). The characterization of older persons how present at a tertiary emergency unit; in particular the contribution of adverse drug events: a cross-sectional study. *Journal of Chemical Information and Modeling*, *53*(July), 1–82. http://library.wur.nl/WebQuery/wurpubs/fulltext/353506

Tiranini, L. (2022). *Recent advances in understanding / management of premenstrual dysphoric disorder / premenstrual syndrome*. *11*.

Tuccinardi, D., Watanabe, M., Masi, D., Monte, L., Meffe, L. B., Cavallari, I., Nusca, A., Maddaloni, E., Gnessi, L., Napoli, N., Manfrini, S., & Grigioni, F. (2024). Rethinking weight loss treatments as cardiovascular medicine in obesity, a comprehensive review. *European Journal of Preventive Cardiology*, *31*(10), 1260–1273. https://doi.org/10.1093/eurjpc/zwae171

Udoetuk, J. D., Dai, Y., Ying, G., Daniel, E., Gangaputra, S., Rosenbaum, J. T., Suhler, E. B., Thorne, J. E., Foster, C. S., & Jabs, D. A. (2013). *Risk of corticosteroid-induced hyperglycemia requiring medical therapy among patients with inflammatory eye diseases*. *119*(8), 1569–1574. https://doi.org/10.1016/j.ophtha.2012.01.043.Risk

van den Anker, J., Reed, M. D., Allegaert, K., & Kearns, G. L. (2018). Developmental Changes in Pharmacokinetics and Pharmacodynamics. *Journal of Clinical Pharmacology*, *58*(May), S10–S25. https://doi.org/10.1002/jcph.1284

Van Norman, G. A. (2023). Off-Label Use vs Off-Label Marketing of Drugs: Part 1: Off-Label Use—Patient Harms and Prescriber Responsibilities. *JACC: Basic to Translational Science*, *8*(2), 224–233. https://doi.org/10.1016/j.jacbts.2022.12.011

Vega, A. J., Smith, C., Matejowsky, H. G., Thornhill, K. J., Borne, G. E., Mosieri, C. N., Shekoohi, S., Cornett, E. M., & Kaye, A. D. (2023). Warfarin and Antibiotics: Drug Interactions and Clinical Considerations. *Life*, *13*(8), 1–11. https://doi.org/10.3390/life13081661

Volkan, K. (2020). Schizophrenia: Epidemiology, Causes, Neurobiology, Pathophysiology, and Treatment. *Journal of Health and Medical Sciences*, *3*(4), 487–521. https://doi.org/DOI: 10.31014/aior.1994.03.04.143

Wang, H. (2011). Agents that induce pseudo-allergic reaction. *Drug Discoveries & Therapeutics*, *5*(5). https://doi.org/10.5582/ddt.2011.v5.5.211

Warrington, R., Silviu-Dan, F., & Wong, T. (2018). Drug allergy. *Allergy, Asthma and Clinical Immunology*, *14*(s2), 1–11. https://doi.org/10.1186/s13223-018-0289-y

White, P. F., White, L. M., Monk, T., Jakobsson, J., Raeder, J., Mulroy, M. F., Bertini, L., Torri, G., Solca, M., Pittoni, G., & Bettelli, G. (2012). Perioperative care for the older outpatient undergoing ambulatory surgery. *Anesthesia and Analgesia*, *114*(6), 1190–1215. https://doi.org/10.1213/ANE.0b013e31824f19b8

Wolff, J., Hefner, G., Normann, C., Kaier, K., Binder, H., Hiemke, C., Toto, S., Domschke, K., Marschollek, M., & Klimke, A. (2021). Polypharmacy and the risk of drug–drug interactions and potentially inappropriate medications in hospital psychiatry. *Pharmacoepidemiology and Drug Safety*, *30*(9), 1258–1268. https://doi.org/10.1002/pds.5310

Wu, X., Cobbina, S. J., Mao, G., Xu, H., Zhang, Z., & Yang, L. (2016). A review of toxicity and mechanisms of individual and mixtures of heavy metals in the environment. *Environmental Science and Pollution Research*, *23*(9), 8244–8259.

https://doi.org/10.1007/s11356-016-6333-x

Yoshimura, Y., Matsumoto, A., & Momosaki, R. (2022). Pharmacotherapy and the Role of Pharmacists in Rehabilitation Medicine. *Progress in Rehabilitation Medicine*, *7*(0), n/a. https://doi.org/10.2490/prm.20220025

Zhang, Li, Q., Shi, C., & Zhang, X. (2017). Drug-induced pseudoallergy: A review of the causes and mechanisms. *Pharmacology*, *101*(1–2), 104–110. https://doi.org/10.1159/000479878

Zhang, Y. J., Li, S., Gan, R. Y., Zhou, T., Xu, D. P., & Li, H. Bin. (2015). Impacts of gut bacteria on human health and diseases. *International Journal of Molecular Sciences*, *16*(4), 7493–7519. https://doi.org/10.3390/ijms16047493